Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 2003, p. 3831-3839, Vol. 47, No. 12
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.12.3831-3839.2003
Copyright © 2003, American
Society for
Microbiology. All Rights Reserved.
Novel Antibacterial Class
Peter J. Dandliker,* Steve D. Pratt, Angela M. Nilius, Candace Black-Schaefer, Xiaoan Ruan, Danli L. Towne, Richard F. Clark, Erika E. Englund, Rolf Wagner, Moshe Weitzberg, Linda E. Chovan, Robert K. Hickman, Melissa M. Daly, Stephan Kakavas, Ping Zhong, Zhensheng Cao, Caroline A. David, Xiaoling Xuei, Claude G. Lerner, Niru B. Soni, Mai Bui, Linus L. Shen, Yingna Cai, Philip J. Merta, Anne Y. C. Saiki, and Bruce A. Beutel
Global
Pharmaceutical Research and Development, Abbott Laboratories, Abbott
Park, Illinois 60064
Received 13 May 2003/
Returned for modification 16 June 2003/
Accepted 26 August 2003
We
report the discovery and characterization of a novel ribosome inhibitor
(NRI) class that exhibits selective and broad-spectrum antibacterial
activity. Compounds in this class inhibit growth of many gram-positive
and gram-negative bacteria, including the common respiratory pathogens
Streptococcus pneumoniae, Haemophilus influenzae,
Staphylococcus aureus, and Moraxella catarrhalis, and
are nontoxic to human cell lines. The first NRI was discovered in a
high-throughput screen designed to identify inhibitors of cell-free
translation in extracts from S. pneumoniae. The chemical
structure of the NRI class is related to antibacterial quinolones, but,
interestingly, the differences in structure are sufficient to
completely alter the biochemical and intracellular mechanisms of
action. Expression array studies and analysis of NRI-resistant mutants
confirm this difference in intracellular mechanism and provide evidence
that the NRIs inhibit bacterial protein synthesis by inhibiting
ribosomes. Furthermore, compounds in the NRI series appear to inhibit
bacterial ribosomes by a new mechanism, because NRI-resistant strains
are not cross-resistant to other ribosome inhibitors, such as
macrolides, chloramphenicol, tetracycline, aminoglycosides, or
oxazolidinones. The NRIs are a promising new antibacterial class with
activity against all major drug-resistant respiratory
pathogens.
* Corresponding
author. Mailing address: Abbott Laboratories, Department R4CP, Building
AP52-N, 200 Abbott Park Rd., Abbott Park, IL 60064-6217. Phone: (847)
938-4841. Fax: (847) 938-3403. E-mail:
peter.dandliker{at}abbott.com.
Antimicrobial Agents and Chemotherapy, December 2003, p. 3831-3839, Vol. 47, No. 12
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.12.3831-3839.2003
Copyright © 2003, American
Society for
Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Mott, J. E., Shaw, B. A., Smith, J. F., Bonin, P. D., Romero, D. L., Marotti, K. R., Miller, A. A.
(2008). Resistance mapping and mode of action of a novel class of antibacterial anthranilic acids: evidence for disruption of cell wall biosynthesis. J Antimicrob Chemother
62: 720-729
[Abstract]
[Full Text]
-
Buurman, E. T., Johnson, K. D., Kelly, R. K., MacCormack, K.
(2006). Different Modes of Action of Naphthyridones in Gram-Positive and Gram-Negative Bacteria. Antimicrob. Agents Chemother.
50: 385-387
[Abstract]
[Full Text]
-
Lerner, C. G., Kakavas, S. J., Wagner, C., Chang, R. T., Merta, P. J., Ruan, X., Metzger, R. E., Beutel, B. A.
(2005). Novel Approach to Mapping of Resistance Mutations in Whole Genomes by Using Restriction Enzyme Modulation of Transformation Efficiency. Antimicrob. Agents Chemother.
49: 2767-2777
[Abstract]
[Full Text]
-
Shen, L. L., Black-Schaefer, C., Cai, Y., Dandliker, P. J., Beutel, B. A.
(2005). Mechanism of Action of a Novel Series of Naphthyridine-Type Ribosome Inhibitors: Enhancement of tRNA Footprinting at the Decoding Site of 16S rRNA. Antimicrob. Agents Chemother.
49: 1890-1897
[Abstract]
[Full Text]
-
Pratt, S. D., David, C. A., Black-Schaefer, C., Dandliker, P. J., Xuei, X., Warrior, U., Burns, D. J., Zhong, P., Cao, Z., Saiki, A. Y. C., Lerner, C. G., Chovan, L. E., Soni, N. B., Nilius, A. M., Wagenaar, F. L., Merta, P. J., Traphagen, L. M., Beutel, B. A.
(2004). A Strategy for Discovery of Novel Broad-Spectrum Antibacterials Using a High-Throughput Streptococcus pneumoniae Transcription/Translation Screen. J Biomol Screen
9: 3-11
[Abstract]